Login / Signup

Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).

Jame AbrahamRobert ColemanAnthony EliasFrankie Ann HolmesKevin KalinskyMuaiad KittanehElyse LowerReshma L MahtaniE Terry MamounasMark PegramCharles Vogelnull null
Published in: Breast cancer research and treatment (2018)
Thus far, three CDK 4/6 inhibitors-palbociclib, ribociclib, and more recently, abemaciclib-have been approved for use in the setting of HR+, HER2-, mBC.  The degrees to which these agents differ in terms of CDK4/6 affinity, side-effect profiles, dosing, degree of central nervous system (CNS) penetration, optimal use in combination with antiestrogen therapy, and across other subsets of breast cancer, remain an active area of investigation.
Keyphrases